Archives of Pharmacal Research

  • 제27권5호
  • /
  • Pages.502-506
  • /
  • 2004
  • /
  • 0253-6269(pISSN)
  • /
  • 1976-3786(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

Antituberculosis Agents X. Synthesis and Evaluation of In Vitro Antituberculosis Activity of 2-(5-Nitro-2-furyl)-and 2-(1-Methyl-5-nitro-1H-imidazol-2-yl)-1 ,3,4-thiadiazole Derivatives

  • Alireza-Foroumadi (Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran) ;
  • Fatemeh-Soltani (Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Ira) ;
  • Raheleh-Jabini (Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Ira) ;
  • Moshafi, Mohammad-Hasan (Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Ira) ;
  • Rasnani, Fatemeh-Mohammadian (Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Ira)
  • 발행 : 2004.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Two series of 2-(5-nitro-2-furyl)- and 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-5-propyl, allyl and propargyl)thio-1,3,4-thiadiazoles (6a-f) and 2-(5-nitro-2-furyl)- and 2-(1-methyl-5-nitro-1 H-imidazol-2-yl)-5-(nitrobenzyl)thio-1,3,4-thiadiazole derivatives (8a-f) have been synthesized and evaluated against Mycobacterium tuberculosis, as part of the TAACF TB screening program under direction of the US National Institute of Health, the NIAID division. Primary screening was conducted at a single concentration, 6.25 $\mu\textrm{g}$mL$^{-1}$ , against M. tuberculosis H$_{37}$ Rv in BACTEC 12B medium, using the Microplate Alamar Blue Assay (MABA). The minimum inhibitory concentration (MIC) was determined for the compounds that demonstrated $\geq$90% growth inhibition in the primary screening. A varying degree of antituberculosis activity (from 0-97% of growth inhibition) was observed with the alkylthio series (6a-f), and the nitroimidazole derivative with a propylthio group (6b) and the nitrofuran derivative with a propargylthio group (6e), were the most active compounds (MIC=3.13 and 1.56 /$\mu\textrm{g}$mL$^{-1}$ , respectively). Among the nitrobenzylthio derivatives (8a-f), all the ortho, meta and para nitrobenzyl isomers in the nitrofuran series exhibited good antituberculosis activity (MIC=3.13 $\mu\textrm{g}$mL$^{-1}$ ), while the corresponding nitroimidazole analogues were completely inactive (Inhibition=0%).

키워드

참고문헌

  1. Collins, L. and Franzblau, S. G., Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium, Antimicrob. Agents Chemother., 41, 1004-1009 (1997)
  2. Foroumadi, A., Asadipour, A., Mirzaei, M., Karimi, J., and Emami, S., Antituberculosisagents. V. Synthesis, evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(5-nitro-2-furyl)-1,3,4-thiadiazole derivatives. Farmaco, 57, 765-769 (2002) https://doi.org/10.1016/S0014-827X(02)01277-6
  3. Foroumadi, A., Daneshtalab, M., and Shafiee, A., Synthesis and in antifungal activity of 2-aryl-5-phenylsulfonyl-1,3,4-thiadiazolederivatives. Arzneim. -Forsch./Drug Res., 49, 1035-1038 (1999)
  4. Foroumadi, A., Mirzaei, M., and Shafiee, A., Antituberculosis agents I: synthesis and antituberculosis activity of 2-ary-1,3,4-thiadiazole derivatives. Pharmazie, 56, 610-612 (2001a)
  5. Foroumadi, A., Mirzaei, M., and Shafiee A., Antituberculosis agents II: Evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole derivatives. Farmaco, 56, 621-623 (2001b) https://doi.org/10.1016/S0014-827X(01)01099-0
  6. Grange, J. M. and Zumla, A., The global emergency of tuberculosis: what is the cause? J. R. Soc. Health, 122, 78-81 (2002) https://doi.org/10.1177/146642400212200206
  7. Gunay, N. S., Capan, G., Ulusoy, N., Ergenc, N., Otuk, G., and Kaya, D., Nitroimidazole derivatives as possible antibacterial and antifungal agents. Farmaco, 54, 826-831 (1999) https://doi.org/10.1016/S0014-827X(99)00109-3
  8. Kaufmann, S. H., Protection against tuberculosis: cytokines, T cells, and macrophages. Ann. Rheum. Dis., 61 (Suppl. 2), ii 54-58 (2002)
  9. Mamolo, M. G., Vio, L., and Banfi, E., Synthesis and antimicrobial activity of some 2,5-disubstituted 1,3,4-thiadiazole derivatives. Farmaco, 51, 71-74 (1996)
  10. Pasqualoto, K. F. and Ferreira, E. I. An approach for the rational design of new antituberculosis agents. Curr. Drug Targets, 2, 427-437 (2001) https://doi.org/10.2174/1389450013348227
  11. Pires, J. R., Saito, C., Gomes, S. L., Giesbrecht, A. M., and Amaral, A. T., Investigation of 5-nitrofuran derivatives: synthesis, antibacterial activity, and quantitative structure-activity relationships. J. Med. Chem., 44, 3673-3681 (2001) https://doi.org/10.1021/jm0101693
  12. Rollas, S., Karakus, S., Durgun, B. B., Kiraz M., and Erdeniz, H., Synthesis and antimicrobial activity of some 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted 1,3,4-thiadiazole derivatives. Farmaco, 51, 811-814 (1996)
  13. Tsotinis, A., Varvaresou, A., Calogeropoulou, T., and Siatra-Papasta Tiligada, A., Synthesis and antimicrobial evaluation of indole containing derivatives of 1,3,4- thiazole, 1,2,4-triazole and their open-chain counterparts. Arzneim forsch., 47, 307-310 (1997)